Tibra Equities Europe’s Krystal Biotech KRYS Stock Holding History

Tibra Equities Europe’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-19,472	Closed	-$641K	–	359
2019 Q1	$641K	Buy	+19,472	New	+$459K	0.06%	237

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Tibra Equities Europe's KRYS Position: Q2 2019 in Review

Tibra Equities Europe sold out of Krystal Biotech (KRYS) in Q2 2019, closing a stake of 19,472 shares — an estimated $641K sold.

Tibra Equities Europe first reported a position in KRYS in Q1 2019 and held it in 1 quarter. The position peaked at $641K in Q1 2019. 76 funds tracked by Wall St. Rank hold KRYS as of Q2 2019.

Tibra Equities Europe reported no remaining Krystal Biotech position as of Q2 2019 after selling out during the quarter.
Tibra Equities Europe sold 19,472 Krystal Biotech shares in Q2 2019, an estimated $641K.
Tibra Equities Europe first reported a position in Krystal Biotech in Q1 2019 and held it in 1 quarter.
Tibra Equities Europe's Krystal Biotech position peaked at $641K in Q1 2019.
76 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2019.

Based on Tibra Equities Europe's 13F filing for Q2 2019, filed 1 Aug 2019.